The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01574651), a randomized phase 3 study. The primary outcome is St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis)..

2. Clinical Question

3. Trial Design

This was a Phase 3, randomized, double-blind, parallel-group study in people with moderate to severe COPD. The official title describes a multicenter study with a 26-week treatment period. The registry reports enrollment of 934 and lists the study as completed. The start is recorded as 2012-05 and primary completion as 2013-04.

The two regimens were designed with matched placebos. One group received QVA149 110/50µg once daily, with placebo versions of tiotropium and formoterol. The other received tiotropium 18µg once daily and formoterol 12µg twice daily, with placebo to QVA149. All listed treatments were for inhalation. Randomization assigns participants to treatment groups by chance; double masking means treatment assignment is concealed from participants and relevant study personnel, although the registry record does not describe exactly who was masked or how masking was maintained.

The primary endpoint was the SGRQ-C total score after 26 weeks, identified as a non-inferiority analysis. The questionnaire covers symptoms, activity limitations and impacts associated with airway disease. The registry also lists a superiority analysis of SGRQ-C and several secondary outcomes, including dyspnea, COPD exacerbations, and lung-function measures. It does not report numerical analyses for those outcomes in the record.

The primary endpoint population was the full analysis set: randomized patients who received at least one dose of randomized study drug. Analysis followed assigned treatment, consistent with the stated intention-to-treat principle. The registry does not report the protocol’s sample-size justification, a detailed analysis plan, or interim-analysis procedures.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis)., measured over Baseline, week 26.

The primary endpoint is the St. George's Respiratory Questionnaire COPD-specific total score after 26 weeks of treatment. The SGRQ is a health-related quality-of-life questionnaire with 40 items covering symptoms, activity and impacts. Symptoms address respiratory symptoms and their severity; activity concerns activities that cause or are limited by breathlessness; and impacts concern social functioning and psychological disturbances due to airway disease.

The total score ranges from 0 to 100, with higher scores indicating poorer health status. It gives a structured way to quantify a patient's reported experience across several related aspects of COPD rather than relying on a single symptom. A mean is the stated summary measure, with standard deviation used to describe variability among observations. The registry identifies the primary analysis as non-inferiority, but does not report the numerical group results, treatment contrast, confidence interval, p-value, or non-inferiority margin. The listed timeframe is baseline and week 26.

For participants who completed the study but had missing SGRQ-C measurements during treatment, the registry says missing values were replaced using last observation carried forward (LOCF). This is an imputation procedure: an earlier recorded score is used in place of a later missing score. The rationale recorded was that symptom scores were expected to improve over treatment, so carrying an earlier score forward was considered conservative by the study record. That rationale does not establish how well the imputed values represent participants' unobserved scores.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Randomized parallel-group design. Randomization assigns participants to treatment groups by chance, which is intended to reduce systematic differences in prognostic characteristics at the time of assignment. A parallel-group design means each participant is assigned to a regimen and followed in that group rather than crossing between regimens as part of the design. In general, randomization supports a fair comparison, but it does not guarantee that groups will be identical or remove the need to report how participants were analyzed.

The registry describes this study as double-blind and lists matched placebo components for both regimens. In general, masking can reduce the influence of treatment expectations on participant reports, clinical decisions and outcome assessment. The registry does not explain which roles were masked, whether masking was assessed, or the details of how it was maintained, so those aspects cannot be evaluated from this record.

Continuous outcome and mean. SGRQ-C total score is a continuous measure on a scale from 0 to 100, where higher scores indicate poorer health status. The registry specifies a mean and standard deviation. In general, a mean conveys the average score in a group, while the standard deviation conveys how dispersed individual scores are around that average. Neither summary by itself gives the precision of a treatment comparison. A confidence interval for a contrast is commonly used to show a range of values compatible with the data under the analysis assumptions; the registry record does not report one for the primary endpoint.

Non-inferiority and superiority. These are different statistical questions. In general, a superiority analysis asks whether evidence supports a difference in a particular direction or whether the groups differ, depending on the specified test. A non-inferiority analysis asks whether the data rule out an unacceptable loss relative to a comparator, defined by a margin set in advance. The registry names both a primary non-inferiority analysis and a secondary SGRQ-C superiority analysis. It does not report the non-inferiority margin, statistical test, confidence interval, p-value, or analysis details. The names of the analyses do not by themselves provide their results.

Analysis population. The stated full analysis set includes all randomized patients who received at least one dose of randomized study drug. The registry says patients were analyzed according to assigned treatment, following the ITT principle, and that this set was used for efficacy variables unless otherwise stated. In general, analyzing participants by randomized assignment preserves the comparison created by randomization. The record does not provide endpoint-specific participant counts, describe exclusions beyond the stated population definition, or report how other deviations from the intended analysis were handled.

Missing measurements. The record says that for participants who completed the study but had missing SGRQ-C measurements during treatment, missing scores were replaced by the last observation carried forward. LOCF substitutes an earlier observed measurement for a later missing one. The registry's stated reasoning is that symptoms were expected to improve, and it characterizes this choice as conservative because it uses an earlier measurement. As a general statistical matter, the direction of bias from LOCF depends on why measurements are missing and how scores change over time; carrying a score forward does not recover the unobserved value. The record does not report sensitivity analyses comparing alternative missing-data assumptions.

Planning calculations. In general, a sample-size calculation is a planning exercise based on assumptions about the effect to detect, variability, significance level, allocation and analysis. It is not evidence about what the trial observed. The registry record describes planning illustrations based on the observed effect, a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a stated fraction of the observed effect. Except for time-to-event illustrations, those calculations are expressed as participants per arm; time-to-event illustrations give the total number of events. These are planning illustrations, not observed power and not the trial's own design justification. The protocol's sample-size justification is not reported in the registry record.

Multiplicity and interpretation. When several outcomes or analyses are examined, the chance of a false-positive finding can rise if each is tested without accounting for the others. General approaches include prespecifying a hierarchy or adjusting the interpretation of multiple tests. The registry lists multiple outcomes and two SGRQ-C analysis labels but does not report a multiplicity strategy or a detailed testing hierarchy. Consequently, no claim about adjustment or confirmatory status can be made from the recorded information.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary SGRQ-C non-inferiority analysis, a secondary SGRQ-C superiority analysis, and other secondary outcomes involving dyspnea, exacerbations, lung function and symptoms. With multiple outcomes or tests, general statistical practice distinguishes prespecified primary questions from additional analyses and considers whether multiplicity affects interpretation. The multiplicity procedure, testing hierarchy and any adjustment are not reported in the registry record. It is therefore not possible to determine from this entry how the analyses were prioritized or how multiple testing was handled.

The listed primary endpoint population is the full analysis set: all randomized patients who received at least one dose of randomized study drug. The registry states that patients were analyzed according to their assigned treatment, following the ITT principle, and that the full analysis set was used for efficacy variables unless otherwise stated. It does not report endpoint-specific analysis counts or give a detailed account of missing outcome data beyond the stated SGRQ-C procedure.

For participants who completed the study but had missing SGRQ-C measurements during treatment, the record says missing measurements were replaced by the last observation carried forward. In general, LOCF assumes that an earlier score is an appropriate stand-in for the missing later score. Its validity depends on the pattern and reasons for missingness and the outcome's trajectory. The record's rationale is that symptom scores were expected to improve, making the approach conservative in the study team's view. Sensitivity analyses and alternative missing-data methods are not reported in the registry record.

Interim analyses, the statistical analysis plan, and the protocol's sample-size justification are not reported in the registry record. Without those details, the extent of prespecification and the full safeguards against selective interpretation cannot be assessed from the entry.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 3% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (0.9%), dyspnoea (0.7%), myocardial infarction (0.6%), rib fracture (0.4%), intervertebral disc protrusion (0.4%).

The registry lists serious adverse-event counts for the two treatment groups. In the QVA149 group, 476 participants were at risk and 30 were recorded with serious adverse events. In the tiotropium-plus-formoterol group, 458 were at risk and 24 were recorded with serious adverse events. For other adverse events, the corresponding at-risk counts are 476 and 458, with 72 and 79 recorded, respectively. These are counts as listed; no comparison of rates or causal interpretation is implied.

The registry also lists serious adverse-event terms with percentages: pneumonia, 0.9%; dyspnoea, 0.7%; myocardial infarction, 0.6%; rib fracture, 0.4%; intervertebral disc protrusion, 0.4%; and pulmonary embolism, 0.4%. The record does not provide term-specific denominators or group-specific breakdowns alongside these percentages, so they should not be treated as treatment-group rates. The death counts are not reported in the registry record.

Adverse-event summaries describe events recorded during a study; they do not by themselves establish that a treatment caused an event. Differences in counts can reflect the number of participants followed, event definitions and reporting practices. The registry entry does not provide enough detail to assess these issues or to support a causal safety comparison.

12. What the Result Does, and Does Not, Mean

The record establishes that a randomized, double-blind, parallel-group Phase 3 study compared QVA149 with tiotropium plus formoterol in people with moderate to severe COPD. It defines a patient-reported primary endpoint: SGRQ-C total score after 26 weeks, with higher scores indicating poorer health status. It also records the analysis population and a procedure for replacing certain missing SGRQ-C measurements.

What the registry entry does not establish is the numerical result of the primary non-inferiority analysis. It does not give the group means, a treatment contrast, confidence interval, p-value, or non-inferiority margin. Thus, the entry cannot show whether the criterion for non-inferiority was met, how large any difference was, or how precisely an estimate was determined. The outcome label and trial design are not substitutes for those results.

The same distinction applies to the listed secondary endpoints. The registry names outcomes involving SGRQ-C, dyspnea, exacerbations and lung function, but numerical analysis results are not reported in the registry record. Their presence in the outcome list indicates what was planned or tracked in the record, not what the analysis found.

General statistical interpretation requires estimates and uncertainty, considered alongside the study's prespecified decision rules and missing-data assumptions. For non-inferiority, the margin is particularly important; for multiple outcomes, the approach to multiplicity affects interpretation. Those details are not reported. The safety counts and listed adverse-event terms describe recorded events, but do not by themselves attribute events to either regimen.

Accordingly, the record supports a description of the trial question, methods and selected safety counts, but not a conclusion about comparative efficacy or causation. Missing numerical results should not be read as evidence of no difference or as evidence for either treatment.

13. Why This Trial Matters Statistically

This trial is statistically notable for framing a patient-reported health-related quality-of-life measure as its primary endpoint. COPD-related health status is represented through symptoms, activity limitations and impacts, rather than through a physiological measure alone. The SGRQ-C total score therefore reflects several dimensions of reported experience, and its direction must be read correctly: higher values indicate poorer health status.

The primary analysis is labeled non-inferiority, which makes the prespecified margin central to interpretation. General statistical reasoning distinguishes a failure to demonstrate a difference from evidence that a treatment is non-inferior. The latter requires a decision rule and an estimate precise enough relative to the margin. Because the margin and numerical result are not reported in the registry record, this distinction cannot be resolved from the entry.

The study also illustrates why outcome definitions and results need to be read separately. The registry names a primary analysis, a secondary superiority analysis of the same questionnaire, and additional outcomes. Those labels describe questions, not findings. Without numerical results and a reported multiplicity strategy, readers cannot assess the relative evidential weight of the listed analyses.

The missing-data method matters because the endpoint is measured over time and some SGRQ-C measurements were missing during treatment. LOCF is straightforward to describe, but its implications depend on the missingness process and score trajectory. The registry records the rationale for using it but does not report sensitivity analyses.

Finally, the entry contains safety counts as well as efficacy definitions, but counts alone do not establish causality or comparative risk. Taken together, the record is useful for identifying the study design and statistical questions, while its unreported analyses limit what can be concluded from the registry information.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting efficacy is that numerical primary results are not reported in the registry record. The entry supplies the endpoint definition and analysis label but not group summaries, a treatment contrast, a confidence interval, a p-value, or the non-inferiority margin. Without these, the primary statistical question cannot be answered from this record.

The primary outcome is identified as having several categories or time points and is not reduced to one comparison in the record. The listed timeframe is baseline and week 26, but a specific numerical comparison is not reported. The record also lists secondary outcomes without numerical results, so their estimates and uncertainty cannot be assessed.

The registry describes LOCF for missing SGRQ-C measurements among participants who completed the study. It does not report how many measurements were missing, the reasons for missingness, or sensitivity analyses using other assumptions. The stated rationale does not establish that LOCF accurately represents unobserved scores.

Details needed to evaluate the full statistical plan are also not reported: the multiplicity approach, interim analyses, protocol sample-size justification, and endpoint-specific analysis counts. The available entry therefore does not allow readers to assess the planned testing hierarchy or the robustness of the primary analysis.

For safety, the record gives overall serious and other adverse-event counts and selected serious-event terms, but does not report deaths or term-specific denominators and group breakdowns. These limitations constrain interpretation of comparative safety as well as efficacy. The absence of these details from the registry record is a limitation of what can be assessed from the entry, not evidence about the underlying trial findings.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) — NCT01574651.
• Registry record last updated 2014-05-22; status last verified 2014-05.
• Results first posted 2014-04-29.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes NCT01574651, a completed Phase 3 randomized, double-blind, parallel-group study sponsored by Novartis Pharmaceuticals. It enrolled 934 people with moderate to severe COPD and compared QVA149 110/50µg once daily with tiotropium 18µg once daily plus formoterol 12µg twice daily, using matched placebos. The official title describes a multicenter, 26-week treatment study.

The primary endpoint was SGRQ-C total score after 26 weeks, labeled as a non-inferiority analysis. The record defines the questionnaire, its score direction, the full analysis set and LOCF handling for certain missing measurements. It lists secondary outcomes involving quality of life, dyspnea, exacerbations and lung function.

Numerical primary and secondary efficacy results, the non-inferiority margin, multiplicity strategy, interim-analysis procedures and protocol sample-size justification are not reported in the registry record. Safety counts and selected serious adverse-event terms are listed, but they do not establish causation.